KT-253
kymera therapeutics
['leukemia', 'kymera ']
kymera therapeutics presents data demonstrating superior efficacy of kt-253, a potent and selective heterobifunctional mdm2 degrader, compared to small molecule inhibitor in preclinical leukemia models at the european hematology association congress -... 
Real-Time News, Market Data, Insider Trades, and Stock Quotes for Biotech, Pharma, Medical, and Healthcare Stocks @ https://t.co/Oqp6BRBKy2